Scandinavian ChemoTech: Starting the year on the right foot - Redeye

Redeye provides an update on Scandinavian ChemoTech following the strong Q1 2024 report. Net sales came in 77% above our estimates, at cSEK1.3m, and the cost control from the company was impressive. We increase our sales estimates, lower the cost base slightly, and increase our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1001668/scandinavian-chemotech-starting-the-year-on-the-right-foot?utm_source=finwire&utm_medium=RSS